For some biotechs, it’s too late but dealmaking has picked up considerably, and the XBI is ending the year at a four-year high. IPOs won’t be back for a while but there is much for biotech and pharma to look forward to in 2026.
Share:
Which corners of the market are set to benefits from this change in fortunes first? In this webinar, we take a closer look at the short-term horizons to explore the companies, therapy areas and drugs that will take center stage in 2026. We also look at the broader market forces shaping this much-needed recovery.
The webinar will explore the anticipated recovery in the biotech and pharma markets, focusing on the companies, drugs, and therapy areas expected to lead in 2026. Key topics include top-selling drugs, fastest-growing companies, major launches, and the impact of market forces such as FDA changes and China’s growing influence.
This webinar provides actionable insights into the short-term and long-term outlook for biotech and pharma, including data on IPOs, VC funding, M&A activity, and FDA approval predictions. Attendees will gain a deeper understanding of pipeline innovation, market recovery signals, and the evolving competitive landscape—, essential for portfolio managers, business development leaders, and C-suite executives.
The webinar is designed for professionals across the pharma and biotech sectors, including business development, portfolio management, finance, and consulting. Participants will learn about emerging pipeline products, the future of GLP-1s, the impact of regulatory changes, and how global trends, especially in China, are shaping the industry’s future.
